Johnson & Johnson Shows Strong Earnings in Q3
On a notable Tuesday, Johnson & Johnson (JNJ) reported impressive financial results for its third quarter, showcasing the resilience of its business. The company announced an adjusted EPS of $2.42, reflecting a decrease of 9.0% compared to the previous year, yet exceeding the consensus expectation of $2.21. Additionally, the pharmaceutical giant's sales reached $22.47 billion, marking a year-over-year increase of 5.2% and surpassing the anticipated $22.16 billion.
Growth Powered by Innovative Medicines
The operational growth for the quarter stood at 6.3%, while the adjusted operational growth was reported at 5.4%. The Innovative Medicine segment was particularly robust, with sales climbing to $14.58 billion, a rise of 4.9% and 6.3% on an adjusted operational basis. This growth was primarily fueled by strong performances from key products, including Darzalex (daratumumab), Erleada (apalutamide), Carvykti (ciltacabtagene autoleucel), Tremfya (guselkumab), Spravato (esketamine), and Opsumit (macitentan).
Performance of Major Products
While several products thrived, sales from Stelara (ustekinumab) and Simponi/Simponi ARIA (golimumab) showed a decline, partially offsetting overall growth. Specifically, Stelara's sales dropped by 5.7% to $2.68 billion, whereas Darzalex experienced a remarkable 22.9% rise, reaching $3.02 billion. Notably, the cancer cell therapy Carvykti generated sales of $286 million, reflecting an impressive year-over-year increase of approximately 87.6%.
MedTech Revenue Growth
In the MedTech sector, worldwide operational sales increased by 6.4%. This growth was significantly influenced by strategic acquisitions and divestitures, which positively impacted growth by 2.7%. Key drivers included advancements in electrophysiology products, the Abiomed acquisition in cardiovascular health, contact lenses in vision care, and wound closure products in general surgery. However, sales were somewhat dampened by declines in endocutter products within advanced surgery.
Revised Financial Guidance
Looking ahead, Johnson & Johnson updated its full-year 2024 adjusted operational EPS guidance in light of a strong performance and the recent acquisition of V-Wave. The impact of this acquisition has prompted the company to forecast expected operational sales for the fiscal year at between $89.4 billion and $89.8 billion, an adjustment from earlier estimates of $89.2 billion to $89.6 billion.
Expected Sales and EPS for 2024
Furthermore, the MedTech powerhouse anticipates reported sales for 2024 in the range of $88.4 billion to $88.8 billion, an upward revision from the prior guidance of $88 billion to $88.4 billion. The consensus expectation now stands at $88.51 billion. Johnson & Johnson also projects adjusted EPS in the range of $9.88 to $9.98, a slight decline from previous guidance of $9.97 to $10.07 and compared to the consensus of $9.84. For adjusted operational EPS, the projected range is $9.86 to $9.96, down from previous estimates of $10.00 to $10.10.
Research and Development Adjustments
Recently, Johnson & Johnson has made significant strategic adjustments in its Communicable Diseases R&D portfolio. This included the discontinuation of a Phase 2 field study aimed at evaluating the efficacy of the investigational antiviral candidate mosnodenvir for preventing the dengue virus in adults aged 18-65, signaling a shift in focus within the company's research initiatives.
Market Response
Following the announcement of these results, JNJ's stock saw a decline of 1.29%, listing at $159.52 in premarket trading. This reflects the cautious approach investors often take following substantial earnings announcements, especially in light of revised guidance and acquisitions.
Frequently Asked Questions
What were Johnson & Johnson's Q3 earnings results?
Johnson & Johnson reported an adjusted EPS of $2.42 and sales of $22.47 billion for Q3, both exceeding analysts' estimates.
What drove the growth in Johnson & Johnson's sales?
The growth was primarily driven by strong sales in the Innovative Medicines segment, particularly cancer treatments like Darzalex and Carvykti.
How did the recent acquisition affect their financial outlook?
The acquisition of V-Wave prompted the company to revise its 2024 sales and EPS guidance, indicating improved performance expectations.
What impact did R&D changes have?
The discontinuation of the dengue virus antiviral study highlights a strategic shift in Johnson & Johnson’s research focus in Communicable Diseases.
What is the current stock price trend for JNJ?
Johnson & Johnson’s stock price dropped by 1.29% to $159.52 after the Q3 earnings announcement.
